drugset / Trial / NCT00038311

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

NCT00038311 ↗

Phase 3 Completed 120 enrolled Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of an investigational drug in the prevention of thrombocytopenia in patients with high-risk sarcoma receiving AI (Adriamycin/Ifosfamide) chemotherapy.

Timeline

Start
2000-09
Primary completion
—
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PN-152,243)/PN-196,444 Unknown — —

Indications